ANDA 211397, held by Acertis Pharmaceuticals. Albuterol Sulfate.
As of Nov 19, 2026, ANDA 211397 (Albuterol Sulfate), held by Acertis Pharmaceuticals, was first approved by FDA on Oct 26, 2018, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 26, 2018 | Original application | Approved | None posted |
| Albuterol SulfateEQ 2MG BASE · tablet;oral | Albuterol Sulfate | Rx |
| Albuterol SulfateEQ 4MG BASE · tablet;oral | Albuterol Sulfate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters